Helix Biomedix Stock Performance
| HXBM Stock | USD 2.70 0.95 54.29% |
The company retains a Market Volatility (i.e., Beta) of -2.5, which attests to a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Helix BioMedix are expected to decrease by larger amounts. On the other hand, during market turmoil, Helix BioMedix is expected to outperform it. At this point, Helix BioMedix has a negative expected return of -0.13%. Please make sure to check out Helix BioMedix's variance, skewness, as well as the relationship between the Skewness and day typical price , to decide if Helix BioMedix performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Helix BioMedix has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unfluctuating performance, the Stock's fundamental drivers remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors. ...more
Helix |
Helix BioMedix Relative Risk vs. Return Landscape
If you would invest 350.00 in Helix BioMedix on November 13, 2025 and sell it today you would lose (80.00) from holding Helix BioMedix or give up 22.86% of portfolio value over 90 days. Helix BioMedix is currently does not generate positive expected returns and assumes 8.4335% risk (volatility on return distribution) over the 90 days horizon. In different words, 75% of pink sheets are less volatile than Helix, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Helix BioMedix Target Price Odds to finish over Current Price
The tendency of Helix Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 2.70 | 90 days | 2.70 | about 39.82 |
Based on a normal probability distribution, the odds of Helix BioMedix to move above the current price in 90 days from now is about 39.82 (This Helix BioMedix probability density function shows the probability of Helix Pink Sheet to fall within a particular range of prices over 90 days) .
Helix BioMedix Price Density |
| Price |
Predictive Modules for Helix BioMedix
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Helix BioMedix. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Helix BioMedix Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Helix BioMedix is not an exception. The market had few large corrections towards the Helix BioMedix's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Helix BioMedix, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Helix BioMedix within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.08 | |
β | Beta against Dow Jones | -2.5 | |
σ | Overall volatility | 0.62 | |
Ir | Information ratio | -0.03 |
Helix BioMedix Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Helix BioMedix for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Helix BioMedix can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Helix BioMedix generated a negative expected return over the last 90 days | |
| Helix BioMedix has high historical volatility and very poor performance | |
| Helix BioMedix has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 1.81 M. Net Loss for the year was (2.58 M) with profit before overhead, payroll, taxes, and interest of 1.16 M. | |
| Helix BioMedix currently holds about 216.53 K in cash with (1.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.31. |
Helix BioMedix Fundamentals Growth
Helix Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Helix BioMedix, and Helix BioMedix fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Helix Pink Sheet performance.
| Return On Equity | -1.23 | |||
| Return On Asset | -0.59 | |||
| Profit Margin | (1.25) % | |||
| Operating Margin | (1.17) % | |||
| Current Valuation | 7.13 M | |||
| Shares Outstanding | 165.72 K | |||
| Price To Earning | (3.03) X | |||
| Price To Book | 4.32 X | |||
| Price To Sales | 2.81 X | |||
| Revenue | 1.81 M | |||
| EBITDA | (2.33 M) | |||
| Cash And Equivalents | 216.53 K | |||
| Cash Per Share | 1.31 X | |||
| Book Value Per Share | 6.94 X | |||
| Cash Flow From Operations | (1.82 M) | |||
| Earnings Per Share | (15.59) X | |||
| Total Asset | 2.26 M | |||
| Retained Earnings | (48.09 M) | |||
| Current Asset | 1.21 M | |||
| Current Liabilities | 520 K | |||
About Helix BioMedix Performance
By examining Helix BioMedix's fundamental ratios, stakeholders can obtain critical insights into Helix BioMedix's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Helix BioMedix is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Helix BioMedix, Inc. operates as a specialty dermatology and consumer products skin health company in the United States. Helix BioMedix, Inc. was founded in 1988 and is headquartered in Bothell, Washington. Helix Biomedix operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 8 people.Things to note about Helix BioMedix performance evaluation
Checking the ongoing alerts about Helix BioMedix for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Helix BioMedix help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Helix BioMedix generated a negative expected return over the last 90 days | |
| Helix BioMedix has high historical volatility and very poor performance | |
| Helix BioMedix has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 1.81 M. Net Loss for the year was (2.58 M) with profit before overhead, payroll, taxes, and interest of 1.16 M. | |
| Helix BioMedix currently holds about 216.53 K in cash with (1.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.31. |
- Analyzing Helix BioMedix's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Helix BioMedix's stock is overvalued or undervalued compared to its peers.
- Examining Helix BioMedix's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Helix BioMedix's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Helix BioMedix's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Helix BioMedix's pink sheet. These opinions can provide insight into Helix BioMedix's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Helix Pink Sheet
Helix BioMedix financial ratios help investors to determine whether Helix Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Helix with respect to the benefits of owning Helix BioMedix security.